Myeloma idiotype (Id)

The Myeloma idiotype represents the unique collection of antigenic determinants, or idiotopes, found within the variable regions of the monoclonal immunoglobulin (M-protein) secreted by malignant plasma cells (Massaia et al., 1999; Janeway et al., 2001). Because each B-cell clone undergoes unique genetic rearrangement, the resulting idiotype serves as a highly specific tumor-associated antigen that is unique to the individual patient's cancer (NCI Dictionary of Cancer Terms). This specificity makes it an ideal target for personalized immunotherapy, particularly idiotype vaccines, which aim to prime the patient's immune system to recognize and destroy the malignant clone (Yi et al., 1997). In clinical practice, the idiotype is often purified from the patient's serum or produced recombinantly, then conjugated to carrier proteins like Keyhole Limpet Hemocyanin (KLH) to enhance its visibility to the immune system (Massaia et al., 1999). While the approach is theoretically sound and has shown the ability to induce specific T-cell responses, its widespread adoption has been hindered by the logistical burden of custom manufacturing and the modest clinical efficacy observed in large-scale trials (Brossart et al., 2000). Modern research continues to explore the idiotype as a target for more potent modalities, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies.

Other names

M-protein idiotypeMonoclonal immunoglobulin idiotypeB-cell receptor idiotypeTumor-specific idiotypeParaprotein idiotype

Active immunotherapy designed to elicit a patient-specific immune response (T-cell and B-cell mediated) against the unique variable region of the monoclonal immunoglobulin expressed by malignant plasma cells.